Buy TB-500 acetate (43aa) 7 mg + Fragment TB-500(1-4)(Ac-SDKP) acetate 4 mg (4aa) + bacteriostatic water 3 ml
€25.45
TB-500 acetate 43aa, 7 mg, plus Ac-SDKP acetate 4 mg and 3 mL bacteriostatic water for controlled peptide analytics and in vitro research. Pharma Research .eu provides documented EU laboratory supply subject to lot-specific CoA verification.
Buy TB-500 Acetate (43aa) 7 mg + Ac-SDKP Acetate 4 mg with Bacteriostatic Water for Advanced Laboratory Research in Europe
This dual-peptide research format contains an N-acetylated 43-residue thymosin-Ξ²4 sequence, a 4-residue Ac-SDKP fragment, and 3 mL of bacteriostatic water for controlled laboratory preparation. Because βTB-500β is used inconsistently across commercial cataloguesβsometimes referring to full-length 43-residue thymosin Ξ²4 and sometimes to a shorter fragmentβthe exact sequence, salt form and batch documentation must be verified before procurement. Pharma Research .eu should supply a lot-specific CoA and SDS for each component.paramountpeptides+2
Uncompromising Purity and Analytical Characterisation
The 7 mg component is described here as an N-acetylated 43-amino-acid peptide corresponding to thymosin Ξ²4. The reported sequence is:
Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser
The 4 mg component is N-acetyl-seryl-aspartyl-lysyl-proline, written as Ac-SDKP. Ac-SDKP is a naturally occurring tetrapeptide associated with the N-terminal sequence of thymosin Ξ²4; its reported molecular mass is approximately 487.5 Da.pmc.ncbi.nlm.nih+1
For procurement, the appropriate release target should be β₯99.0% purity by RP-HPLC for each peptide, but this value must be treated as a proposed specification until confirmed by the actual batch CoA. The analytical package should distinguish the 43-residue peptide from shorter thymosin Ξ²4 fragments. This distinction is particularly important because some commercial sources label a seven-residue peptide, Ac-LKKTETQ, as βTB-500β, whereas the product specified here is a 43-residue material.absolutebiolab+1
A complete CoA should include:
-
RP-HPLC chromatogram and reported purity for the 43-residue peptide.
-
RP-HPLC chromatogram and reported purity for Ac-SDKP.
-
LC-MS, ESI-MS or LC-HRMS identity confirmation.
-
Reported sequence and N-terminal acetylation status.
-
Salt or counter-ion designation, including acetate content where applicable.
-
Visual appearance and lyophilised mass.
-
Residual-solvent results from peptide synthesis and purification.
-
Water or residual-moisture content, where tested.
-
Elemental impurity or heavy-metal results where included in the vendorβs specification.
-
Lot number, manufacture date, retest date and storage requirements.
Residual solvents and heavy metals should be reported against a defined analytical method and specification. Exact numerical limits should not be inserted into a product page without the manufacturerβs verified quality standard. Similarly, βacetateβ may describe a counter-ion rather than a change to the peptide backbone, so the CoA should identify whether the reported molecular mass is for the free peptide, acetate salt or another formulated form.
Both peptide components are normally supplied as white to off-white lyophilised solids. Visual inspection can identify gross abnormalities such as discolouration, collapse or visible contamination, but it cannot establish identity or purity. Chromatographic separation and mass-spectral confirmation are required for analytical release.
This level of characterisation is important because long peptides may generate deletion sequences, oxidation products, truncated chains and other process-related impurities. The 43-residue sequence contains methionine, which may be susceptible to oxidation during storage or handling. Such variants can alter chromatographic profiles, molecular-ion distributions and biological assay interpretation. Ac-SDKP can also require separate chromatographic verification because its small size and high polarity produce analytical behaviour distinct from the parent peptide.
Principal Laboratory Applications and Research Methodologies
This dual-peptide format is suited to controlled laboratory research involving peptide analytics, synthetic-peptide characterisation and in vitro pathway studies. All work should be performed by qualified personnel within an appropriately governed university, CRO, pharmaceutical R&D or analytical laboratory.
Peptide identity and impurity profiling. The 43-residue material can be used to develop or validate RP-HPLC and LC-MS methods for long-peptide analysis. Analysts may monitor the intact molecular ion, oxidation products, truncated sequences and synthesis-related deletion impurities. Ac-SDKP should be analysed using a method suitable for a low-molecular-weight acetylated tetrapeptide rather than assuming that the parent-peptide method will provide adequate resolution.
Comparative peptide-characterisation studies. Laboratories may compare the 43-residue thymosin Ξ²4 material with Ac-SDKP to examine retention behaviour, ionisation efficiency, degradation patterns and matrix effects. This can support method development for complex peptide mixtures, reference-solution preparation and stability-indicating assays.
In vitro receptor and cell-signalling models. The separate components may be evaluated in controlled cellular systems to investigate peptide-associated signalling or pathway responses. Appropriate experimental design should include vehicle controls, matrix controls, concentration verification and analytical confirmation of peptide integrity during the incubation period. Results should not be attributed to one peptide if the formulation contains both components without component-specific controls.
Chemical and formulation stability research. The material may be used in forced-degradation studies examining temperature, light, pH, oxidation and freezeβthaw stress. Such studies can help laboratories establish an assay-specific storage window and determine whether the 3 mL bacteriostatic-water component is compatible with the intended analytical matrix.
Bacteriostatic water should be treated as a separate reagent with its own formulation, preservative profile, expiry date and documentation. Its compatibility with chromatography, mass spectrometry and cell-based assays must be assessed experimentally. Preservatives or excipients can affect cell viability, adsorption to laboratory plastics, chromatographic background or ion suppression.
The presence of two peptides in one presentation creates an additional procurement consideration: a combined vial may not provide the same analytical control as individually packaged components. The CoA should state whether the 7 mg and 4 mg quantities are supplied in separate vials or as a combined mixture, and it should report the identity and purity of each component independently.
Compound Stability, Optimal Storage, and Safe Handling Protocols
Lyophilised peptides should generally be stored sealed, dry and protected from light. A long-term condition of approximately β20Β°C is commonly used for peptide research materials, although the lot-specific CoA takes precedence. Some laboratories may use β80Β°C for extended storage where supported by their stability programme. Commercial research references describe sealed, desiccated, light-protected storage as important for maintaining peptide integrity.americanpeptides+1
Recommended controls include:
-
Keep unopened vials at β20Β°C or the temperature stated on the CoA.
-
Protect the lyophilised material from light and moisture.
-
Allow a sealed vial to equilibrate before opening to minimise condensation.
-
Use low-binding tubes and aliquots for prepared research solutions where appropriate.
-
Avoid repeated freezeβthaw cycles.
-
Store short-term aqueous working solutions at 2β8Β°C only when supported by validation.
-
Use frozen aliquots for longer-term solution storage when stability data support that approach.
-
Record reconstitution solvent, concentration, date, operator and storage history.
The 3 mL water presentation does not establish a universal reconstitution protocol. If the full nominal quantities were dissolved into the complete 3 mL volume, the theoretical concentrations would be approximately 2.33 mg/mL for the 43-residue peptide and 1.33 mg/mL for Ac-SDKP, assuming separate dissolution and quantitative transfer. Actual concentrations depend on the final volume, salt form, peptide content, purity, water content and whether the components are packaged separately. These figures are formulation calculations for laboratory preparation, not biological-use instructions.
Reconstitution should be performed using a validated laboratory procedure. Add the aqueous reagent gradually, allow the powder to hydrate, and mix gently to reduce foaming and surface adsorption. Do not assume that bacteriostatic water is interchangeable with sterile water, buffered saline or an organic solvent. The correct medium depends on the analytical or cellular method.
Handling should follow the current SDS and institutional risk assessment. Appropriate controls generally include a certified fume hood or suitable local containment, nitrile gloves, safety goggles and a laboratory coat. Avoid generating dust or aerosols, and do not pipette by mouth. Dispose of peptide-contaminated materials according to institutional chemical and laboratory-waste procedures.
Technical Specifications and Molecular Attributes
| Attribute | TB-500 acetate, 43aa | Ac-SDKP acetate, 4aa |
|---|---|---|
| Product quantity | 7 mg | 4 mg |
| Sequence | Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES | Ac-SDKP |
| Common description | N-acetylated 43-residue thymosin Ξ²4 peptide | N-acetyl-seryl-aspartyl-lysyl-proline |
| IUPAC name | Full systematic peptide name should be confirmed on the CoA; sequence notation is preferable for procurement | Full systematic peptide name should be confirmed on the CoA; sequence notation is preferable |
| CAS Registry Number | CAS assignments vary across catalogues; verify the exact acetate form and sequence on the CoA | 120081-14-3 is reported for Ac-SDKP by some references; verify the supplied form |
| Molecular formula | Approximately CβββHββ βNβ βOββS for the free peptide; acetate-associated reporting can differ | CββHββNβ Oβ for the neutral composition |
| Reported molecular mass | Approximately 4,963 Da for thymosin Ξ²4; acetate and water content may alter the stated product mass | Approximately 487.5 Da |
| Physical state and colour | Lyophilised white to off-white powder | Lyophilised white to off-white powder |
| Solubility profile | Aqueous solubility should be verified experimentally; peptide adsorption and aggregation may occur | Aqueous solubility should be confirmed for the selected assay matrix |
| Typical purity | Proposed target β₯99.0% by RP-HPLC; verify each batch | Proposed target β₯99.0% by RP-HPLC; verify each batch |
| Identity testing | LC-MS, LC-HRMS or peptide mapping | LC-MS or suitable high-resolution chromatographic method |
| Companion reagent | 3 mL bacteriostatic water | 3 mL bacteriostatic water |
| Long-term storage | Typically β20Β°C, sealed, dry and protected from light | Typically β20Β°C, sealed, dry and protected from light |
The nomenclature requires particular care. Some suppliers use βTB-500β for the full-length 43-residue peptide, while others use it for a seven-residue fragment. The product title, sequence, molecular formula and mass should therefore be reconciled before a purchase order is approved.absolutebiolab+2
Pharma Research .eu: Your Premier EU Vendor for High-Purity Reagents
Pharma Research .eu can position this dual-peptide presentation as a traceable European laboratory reagent for teams requiring defined peptide sequences, analytical documentation and controlled procurement. A credible product file should include separate identity and purity information for the 43-residue peptide and Ac-SDKP, together with the SDS and documentation for the bacteriostatic-water component.
Any statement that Pharma Research .eu operates an ISO 9001-certified quality-management system should be supported by a current certificate showing the issuing body, scope and validity. Likewise, claims regarding temperature-controlled logistics across EU member states should be verified for each destination, carrier route and product-handling requirement rather than presented as a universal guarantee.
A quality-focused vendor should be able to discuss:
-
Sequence and N-terminal acetylation.
-
Distinction between 43-residue thymosin Ξ²4 and shorter products marketed as TB-500.
-
Free-peptide versus acetate-associated molecular mass.
-
HPLC purity and mass-spectral identity.
-
Residual solvents, water content and elemental-impurity reporting.
-
Packaging configuration and whether the two peptides are separated.
-
Storage, reconstitution compatibility and transport conditions.
The product should be supplied strictly as a laboratory research reagent for qualified professionals. Before release into a validated workflow, laboratory managers should review the current CoA, SDS, sequence designation, salt form, storage history and applicable institutional requirements.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisqueΒ vestibulum amet elit ut volutpat.


Reviews
There are no reviews yet.